Abingworth Clinical Co-Development (ACCD) Financing
We take 100% of the financial risk. Success payments are due only if the drug is approved and these may include a royalty component. The cost for such funding is targeted to be competitive with internal risk-adjusted costs.
We have an Abingworth Direct Financing option aimed at funding development programs, which are executed by companies independently. Our co-development portfolio companies Launch Tx, SFJ and Avillion bring operational expertise, in addition to capital, to facilitate clinical trial execution globally thereby increasing the speed and quality of the trials.
Addressing Biopharma Needs
ACCD financing enables companies to:
- Access development funding while minimising EPS impact and avoiding costly equity dilution
- Expand pipeline of development programs via life cycle management and geographic expansion
- Leverage the option of global clinical and regulatory teams to execute speedy and high-quality trials
Assets will typically be Phase 3 ready or pivotal, with a high probability of reaching approval and successful commercialisation within a few years. The assets can be new molecular entities (NMEs) or already approved products being trialled in new indications. Single or multiple assets can be considered for global or regional development programs.
Size and Timing
Investment size is typically upwards of $30m. We offer flexible financing solutions across the capital structure, and work with companies to evaluate a combination of equity and CCD financing where appropriate. Diligence is rapid, leading to an initial go/no-go decision in weeks.
Interested to learn more?
If you'd like additional information about Abingworth's pioneering Clinical Co‑Development solution, please contact James CornwallContact James
Seed & Early Stage
With over 30 years of experience investing in novel life science technologies, we understand how challenging it can be to turn a great idea into a great company.Find out more
We also understand the different challenges faced by later-stage companies, both public and private, as their programs move through the clinic to market. Our Development Stage strategy is focused on these later-stage companies.Find out more